Literature DB >> 2013119

Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma.

C J Twelves1, C M Ash, D W Miles, D G Thomas, R L Souhami.   

Abstract

A total of 15 patients with relapsed high-grade glioma were treated with carboplatin (400 mg/m2) or iproplatin (300 mg/m2). All had received previous radiotherapy, and 12 had previously undergone chemotherapy. One of the ten patients treated with carboplatin and one of the five treated with iproplatin achieved a partial remission as determined by repeat computerised tomographic (CT) scan. Myelosuppression was considerable, as three patients developed grade IV neurotoxicity, which was fatal in one case. Although carboplatin and iproplatin showed activity against malignant glioma, the study was closed because of unacceptable toxicity.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2013119     DOI： 10.1007/bf00685164

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  10 in total

1.  Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors.

Authors:  D J Stewart; M Leavens; M Maor; L Feun; M Luna; J Bonura; R Caprioli; T L Loo; R S Benjamin
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

2.  Ovarian trials at the Royal Marsden.

Authors:  E Wiltshaw
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Phase I study of carboplatin (CBDCA) in children with cancer.

Authors:  D M Bacha; B Caparros-Sison; J A Allen; R Walker; C T Tan
Journal:  Cancer Treat Rep       Date:  1986-07

5.  Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study.

Authors:  D J Stewart; R M O'Bryan; M Al-Sarraf; J J Costanzi; N Oishi
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

6.  Carboplatin and recurrent childhood brain tumors.

Authors:  J C Allen; R Walker; E Luks; M Jennings; S Barfoot; C Tan
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

7.  In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin.

Authors:  P Dodion; C Sanders; P Georges; Y Kenis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Activity of JM9 in advanced ovarian cancer: a phase I-II trial.

Authors:  V H Bramwell; D Crowther; S O'Malley; R Swindell; R Johnson; E H Cooper; N Thatcher; A Howell
Journal:  Cancer Treat Rep       Date:  1985-04

9.  Cisplatin therapy in recurrent childhood brain tumors.

Authors:  A B Khan; B J D'Souza; M D Wharam; L A Champion; L F Sinks; S Y Woo; D C McCullough; B G Leventhal
Journal:  Cancer Treat Rep       Date:  1982-12

10.  An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma.

Authors:  S P Stenning; L S Freedman; N M Bleehen
Journal:  Br J Cancer       Date:  1987-07       Impact factor: 7.640
  10 in total
  9 in total

1.  Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma.

Authors:  K Peterson; G Harsh; P G Fisher; J Adler; Q Le
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

2.  RMP-7 : Potential as an Adjuvant to the Drug Treatment of Brain Tumours.

Authors:  A V Boddy; H D Thomas
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

3.  Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor.

Authors:  David Fortin; Joseph A Salamé; Annick Desjardins; Andrew Benko
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

4.  Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study.

Authors:  P Lunardi; J Osman Farah; L Mastronardi; F Puzzilli; F M Lo Bianco
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

5.  A phase II study of intravenous carboplatin for the treatment of recurrent gliomas.

Authors:  R E Warnick; M D Prados; E E Mack; K L Chandler; F Doz; J E Rabbitt; M K Malec
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 6.  Perioperative care of the oncology patient.

Authors:  C J Kelly; J M Daly
Journal:  World J Surg       Date:  1993 Mar-Apr       Impact factor: 3.352

7.  Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.

Authors:  S Cha; E A Knopp; G Johnson; A Litt; J Glass; M L Gruber; S Lu; D Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 4.966

8.  Platinum-based chemotherapy in recurrent high-grade glioma patients: retrospective study.

Authors:  Ermir Roci; Bujar Cakani; Gramoz Brace; Teona Bushati; Arben Rroji; Mentor Petrela; Gentian Kaloshi
Journal:  Med Arch       Date:  2014

9.  Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma.

Authors:  E Franceschi; G Cavallo; L Scopece; A Paioli; A Pession; E Magrini; R Conforti; E Palmerini; S Bartolini; S Rimondini; R Degli Esposti; L Crinò
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.